Phase 2 study of pembrolizumab in patients with advanced rare cancers.

Aung NaingFunda Meric-BernstamBettzy StephenDaniel D KarpJoud HajjarJordi Rodon AhnertSarina A Piha-PaulRivka R ColenCamilo JimenezKanwal P RaghavRenata FerrarottoShi-Ming TuMatthew CampbellLinghua WangSarjeel H SabirCoya TapiaChantale BernatchezMichael FrumovitzNizar TannirVinod RaviSaria KhanJeane M PainterAbulrahman AbonofalJing GongAnas AlshawaLacey M McQuinnMingxuan XuSara AhmedVivek SubbiahDavid S HongShubham PantTimothy A YapApostolia M TsimberidouEcaterina E Ileana DumbravaFilip JankuSiqing FuRichard M SimonKenneth R HessGauri R VaradhacharyMouhammed Amir Habra

Published in: Journal for immunotherapy of cancer (2021)

NCT02721732.

Keyphrases

open label
advanced non small cell lung cancer
double blind
epidermal growth factor receptor
childhood cancer